Drug Dealin

Ever wondered what's really happening behind the scenes in the biotech and pharmaceutical industry? Drug Dealin' pulls back the curtain. Co-hosts Shivu Sharma and Kenny Lalwani, two seasoned BioPharma professionals, offer unparalleled insider insights, dissecting the latest news, trends, and catalysts. Each episode features in-depth discussions and interviews with industry luminaries, giving you honest and unvarnished perspectives you won't find anywhere else.

Drug Dealin is a science podcast hosted by Drug Dealin Pod, with 10 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Drug Dealin Pod hosts Drug Dealin, a science show with 10 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #9

  Ep. 9: Using AI to Find Novel Treatment Options

  Feb 26, 202635 minS0

  <p><b>SUMMARY</b></p><p>In this episode, Shivu and Kenny discuss how you as a caregiver or patient can use public resources like clinicaltrials.gov and Large Language Models (LLMs) like ChatGPT to discover the latest treatment options for a particular disease and empower yourself to have a more productive conversation with your doctor. Kenny and Shivu discuss an example of this situation from an episode of Apple TV's "Shrinking", starring Harrison Ford. In the episode they go through a demo of how they would find new treatment options for Ford's character, a patient suffering from Parkinson's Disease...

  ListenShow Notes
• 

  Episode #8

  Ep. 8: 2026 Predictions

  Jan 29, 20261 hourS0

  <p><b>Summary</b></p><p>In this episode, Shivu and Kenny review their predictions for 2025 and make new predictions for 2026. They discuss trends in mergers and acquisitions, market performance, the impact of AI in drug development, and the rise of digital advertising in the pharmaceutical industry. They also explore the evolving landscape of biotech companies, regulatory changes from the FDA, and the growing interest in metabolic diseases and psychedelics. Finally, they introduce the 'pharm to table' model in pharma, emphasizing direct-to-patient commercial channels and how these increase patient agency. <br /><br /><b>Chapters</b></p><p>00:00 Introduction and Overview...

  ListenShow Notes
• 

  Episode #7

  Ep.7: Biotech M&A Insights: CVRs, Patent Cliffs & The Pfizer-Novo Bidding War

  Nov 20, 20251h 22mS0

  <p>SUMMARY</p><p>In this deep dive into biopharma M&A trends, Shivu and Kenny analyze 10 years of acquisition data from major pharma players, revealing rising deal volumes and the increasing prevalence of Contingent Value Rights (CVRs) as risk mitigation tools. The hosts dissect the unprecedented Pfizer-Novo bidding war over Metsera, examining how this “interloper” situation reflects broader industry dynamics around patent cliffs and portfolio diversification strategies. The episode provides insider perspectives on why investors never seem satisfied with “enough” M&A activity and how companies balance internal R&D with external acquisitions in their portfolio approach.</p><p></p><p>CHA...

  ListenShow Notes
• 

  Episode #6

  Ep. 6: Should the FDA Be Independent?

  Sep 9, 20251h 42mS0

  <p>SUMMARY: In this episode, Shivu and Kenny discuss the recent developments surrounding Replimune and its interactions with the FDA. They explore the implications of leadership changes at the FDA, the importance of patient advocacy, and the challenges faced by small biotech companies in navigating the regulatory landscape. The conversation highlights the critical role of stability in drug approvals and the potential impact on patient care, particularly in oncology. They discuss the complexities of the FDA's role in drug development, the importance of confirmatory studies, and the impact of leadership changes on regulatory processes. They also talk about the historical...

  ListenShow Notes
• 

  Episode #5

  Ep. 5: How to Talk to Doctors | Feat. Joe McCann, Co-Founder/CEO of Slingshot Insights

  Jul 1, 20251h 41mS0

  <p>Summary:</p><p>In this episode we chat with Joe McCann, CEO of Slingshot Insights. Joe estimates he has done somewhere between 5-10K calls interviewing physicians. In today's episode we tap into his insights on how to get more out of your conversations with doctors. Joe opens up his expert playbook on how to prepare and conduct calls with doctors. We also discuss how these tips/tricks can be applied by the everyday person to get more out of your interactions with healthcare practitioners and ensure you are getting the best care possible. </p><p><br /></p><p>...

  ListenShow Notes

Recent guests on Drug Dealin. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.